Clinical Identification of PPI-Induced Acute Interstitial Nephritis
Understanding the Baseline Creatinine Paradox
- Monitor for relative changes from baseline, not absolute values: A rise in serum creatinine of ≥50% from baseline or ≥0.3 mg/dL increase constitutes Grade 1 acute kidney injury, even if the absolute value remains within "normal" laboratory ranges 1, 2, 3
Clinical Identification Algorithm
Laboratory Surveillance Markers
- Serial creatinine monitoring: Any increase ≥50% from patient's baseline warrants investigation, regardless of whether it exceeds laboratory upper limits 1, 2, 3
- Sterile pyuria (≥5 WBCs/hpf) 1
Clinical Context Assessment
- Concomitant nephrotoxic medications (NSAIDs, other nephrotoxins) require heightened surveillance 4
Practical Monitoring Strategy
- Establish baseline creatinine before initiating long-term PPI therapy 5
- Monitor creatinine at strategic intervals: At 4-6 weeks after PPI initiation and every 3-6 months for chronic users 3, 5
Diagnostic Confirmation
- Renal biopsy remains the gold standard, but may not be necessary if temporal relationship is clear, alternative causes are excluded, and improvement occurs with PPI discontinuation 1, 2, 3
- Consider biopsy when diagnosis is uncertain or steroid therapy is being contemplated 4
Management Upon Identification
- Immediately discontinue PPI 4
- Consider corticosteroids (prednisone 0.5-1 mg/kg/day) if creatinine elevation persists or worsens after PPI cessation 1, 2, 4
De-prescribing Consideration
- All patients on chronic PPI therapy without definitive ongoing indication should be considered for de-prescribing 5